BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38156824)

  • 1. Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis.
    Sun Z; Zhang Y; Zhou H; Li J; Zhou Y; Wang L
    Scand J Clin Lab Invest; 2023 Dec; 83(8):540-547. PubMed ID: 38156824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
    Wen N; Zhao N; Xu H; Zhao Y; Ma J
    Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-alpha-trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis.
    He K; He S; Su M
    J Clin Lab Anal; 2022 Mar; 36(3):e24231. PubMed ID: 35064701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.
    Zhang Q; Jin D; Mou X; Ye H
    J Clin Lab Anal; 2022 Mar; 36(3):e24267. PubMed ID: 35104386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Change of Serum Inter-α-Trypsin Inhibitor Heavy Chain H4 and its Relation with Inflammation, Disease Recurrence, and Mortality in Acute Ischemic Stroke Patients.
    Zhang J; Hu J; Zhao W
    Tohoku J Exp Med; 2023 Feb; 259(3):221-227. PubMed ID: 36596502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal change of serum inter-alpha-trypsin inhibitor heavy chain H4, and its correlation with inflammation, multiorgan injury, and death risk in sepsis.
    Zhao X; Guo Y; Li L; Li Y
    J Clin Lab Anal; 2023 Feb; 37(3):e24834. PubMed ID: 36725250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis.
    Li M; Zhou X
    Inflammopharmacology; 2021 Oct; 29(5):1371-1378. PubMed ID: 34406596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.
    Yuan J; Xiang L; Wang F; Zhang L; Liu G; Chang X; Zhang A; Tao Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24472. PubMed ID: 35622982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    Saad CG; Ribeiro AC; Moraes JC; Takayama L; Goncalves CR; Rodrigues MB; de Oliveira RM; Silva CA; Bonfa E; Pereira RM
    Arthritis Res Ther; 2012 Oct; 14(5):R216. PubMed ID: 23062122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JKAP serves as a potential biomarker for the evaluation of inflammatory condition, disease activity, and treatment response to TNF inhibitor in ankylosing spondylitis patients.
    Zhou X; Li M
    Mod Rheumatol; 2022 Apr; 32(3):613-618. PubMed ID: 34918117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
    Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
    Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
    Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
    Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
    Park JH; Kwon OC; Park MC
    Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum PCSK9 is positively correlated with disease activity and Th17 cells, while its short-term decline during treatment reflects desirable outcomes in ankylosing spondylitis patients.
    Cai J; Jiang Y; Chen F; Wu S; Ren H; Wang P; Wang J; Liu W
    Ir J Med Sci; 2023 Aug; 192(4):1785-1791. PubMed ID: 36344709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exploration of the mechanism of xinfeng capsule in the treatment of ankylosing spondylitis based on B and T lymphocyte attenuator and oxidative stress].
    Qi YJ; Liu J; Zheng L; Cao YX; Wan L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jan; 35(1):25-32. PubMed ID: 25790670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between sclerostin level and radiographic changes in patients with ankylosing spondylitis].
    Xie J; Yu X
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(17):1300-4. PubMed ID: 26081658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.